NHS England And Vertex Strike “Lightening Quick” CF Kaftrio/Trikafta Deal
Other Portfolio Style Agreements Could Lead To Quick Access In Other Markets
An agreement between Vertex and NHS England secures rapid access to Kaftrio, the company’s triple therapy for cystic fibrosis, including for patients with rare mutations not covered by the soon-to-be-granted European marketing authorization. The final price will depend on an assessment by health technology appraisal body NICE.
You may also be interested in...
2021: A Record-Breaking Year For ‘Smart’ Pricing And Access Deals In England
NHS England and Improvement (NHSE&I) agreed 16 pricing and access deals with drug companies in 2021, ten of which can be considered ‘smart.’ The fact that these were achieved against a backdrop of COVID-19 is seen as impressive.
Vertex Inks New Cystic Fibrosis Deals In Europe
Reimbursement timelines in Italy and France for the treatments in question have been quicker than the average.
Vertex Secures Rapid Deal In England For CF Triple Therapy
After a long-standing row with payer NHS England, the rapid market access deal will help Vertex move into growth phase.